Arvinas (ARVN)
(Delayed Data from NSDQ)
$35.95 USD
+1.30 (3.75%)
Updated May 22, 2024 04:00 PM ET
After-Market: $35.96 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Arvinas, Inc. [ARVN]
Reports for Purchase
Showing records 161 - 180 ( 204 total )
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Increasing Our PT to $65 - To Reflect Broader Market Potential of ARV-110
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - The Wedbush Monthly Check-Up: May 2020
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Steady Progress With Data on Track to Readout; Reit Buy and Raise PT to $60
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; Prostate Cancer Data at ASCO Just Around the Corner
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Register for Our Webinar: ACSO Abstract Titles Review '-' April 30th at 10am ET
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Reminder to Register for Our Prostate Cancer KOL Call '-' Today at 1pm ET
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Update: Cash Position - 2020 Catalysts of Covered Companies
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Corrected: BEST IDEAS LIST - Adding TCF
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
KOL Call on Prostate Cancer Treatment Landscape '-' April 23rd at 1pm ET
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Update - ARV-110 and ARV-471 Data Release Remains on Track
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z